{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:32Z","timestamp":1787841332389,"version":"build-2784847793"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T00:00:00Z","timestamp":1495065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>More than 70,000 hematopoietic cell transplants are currently performed each year, and these continue to increase every year. However, there is a significant variation in the number of absolute transplants and transplant rates between centers, countries, and global regions. The prospect for emerging countries to develop a hematopoietic cell transplantation (HCT) program, as well as to decide on whether autologous HCT (auto-HCT) or allogeneic HCT (allo-HCT) should be established to start with, relies heavily on factors that can explain differences between these two procedures. Major factors that will influence a decision about establishing the type of HCT program are macroeconomic factors such as organization of the healthcare network, available resources and infrastructure. Prevalence of specific diseases in the region as well genetic background of donors and recipients will also influence the mandate or priority of the HCT in the national healthcare plan to explain some of the country-specific differences. Furthermore, microeconomic factors play a role, such as center-specific experience in treating various disorders requiring hematopoietic stem cell transplantation, along with accreditation status and patient volume. The objective of the transplant procedure was to improve the survival anc quality of life of patients. The regional difference that one notices in emerging countries about the higher number of allo-HCT compared with auto-HCT procedures performed is primarily based on suboptimal healthcare network in treating various malignant disorders that are the primary indication for auto-stem cell transplantation. In this context, nonmalignant disorders such as bone marrow failure syndromes, inherited genetic disorders and hemoglobinopathies have become the major indication for stem cell transplantation. Better understanding of these factors will assist in establishing new transplant centers in the emerging countries to achieve their specific objectives and positive outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.05.016","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T12:46:16Z","timestamp":1499085976000},"page":"173-177","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies"],"prefix":"10.4103","volume":"10","author":[{"given":"Naeem A.","family":"Chaudhri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad I.","family":"Almohareb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazzaa A.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2017.05.016_b0005","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/bmt.2016.18","article-title":"Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey","volume":"51","author":"Niederwieser","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.016_b0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone-marrow transplantation","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.016_b0015","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.016_b0020","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants: a retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hemonc.2017.05.016_b0025","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/S0140-6736(05)67343-6","article-title":"Responding to the threat of chronic diseases in India","volume":"366","author":"Srinath Reddy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2017.05.016_b0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1744-8603-8-14","article-title":"Priorities for developing countries in the global response to non-communicable diseases","volume":"8","author":"Maher","year":"2012","journal-title":"Global Health"},{"key":"10.1016\/j.hemonc.2017.05.016_b0035","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2016.01.012","article-title":"Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions","volume":"22","author":"Kumar","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201710040-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:14Z","timestamp":1787838614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201710040-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.016","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}